Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval for a change in its production license for special medical purpose formula foods, expanding its product range [1][4]. Group 1: License Change - The company has obtained a new production license for special medical purpose formula foods, which includes an expanded range of food categories [1]. - The updated license is issued by the Chongqing Municipal Market Supervision Administration [1]. Group 2: Product Information - The company's Gan Yimei liquid formula food is designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber [2]. - The product provides a high carbohydrate energy ratio of 87%, ensuring quick energy supply with minimal digestive burden, and includes essential vitamins and minerals for balanced nutrition [2]. - It is suitable for nutritional support in conditions such as acute pancreatitis and short bowel syndrome, and can also be used as a standardized liquid diet before colonoscopy [2]. Group 3: Market Potential - The global market for special medical purpose formula foods is estimated to reach $24.8 billion in 2024, with a projected compound annual growth rate (CAGR) of 5.13%, reaching $33.49 billion by 2030 [2]. - In China, the market size for special medical purpose formula foods is estimated at RMB 16.4 billion (approximately $2.27 billion) in 2024, holding the largest revenue share in the Asia-Pacific region, accounting for 9.15% of the global market [2]. - The Chinese market is expected to grow at a CAGR of 6.58%, reaching RMB 24 billion (approximately $3.33 billion) by 2030, indicating significant potential due to low current clinical usage rates compared to developed countries [2].

Group 1 - The core point of the article is that Chongqing Huasen Pharmaceutical Co., Ltd. has received a production license for special medical purpose formula foods, which supports the production of its product "Ganyimei®" [1] - The product "Ganyimei®" is designed for individuals over 10 years old who require strict fat restrictions and have digestive absorption disorders, featuring a scientific formula with 0 fat and 0 fiber, primarily composed of carbohydrates with a high energy supply ratio of 87% [1] - The product is applicable in various scenarios, including nutritional support for acute pancreatitis, short bowel syndrome, and gastrointestinal function damage, as well as standardized liquid diets before colonoscopy [1] Group 2 - According to Grand View Research, the global special medical food market is projected to reach $24.8 billion in 2024 and grow at a compound annual growth rate (CAGR) of 5.13% to $33.49 billion by 2030 [2] - The Chinese market is expected to be approximately 16.4 billion RMB in 2024, accounting for 9.15% of the global market share, with a projected CAGR of 6.58% to reach 24 billion RMB by 2030 [2] - The clinical usage rate of special medical foods in China is currently much lower than in developed countries, indicating significant growth potential as health awareness and clinical nutritional support needs increase [2] - The production license change is a foundational step for the company to expand its special medical food business and is an important measure for enhancing its health industry layout [2]

Healthcare Policy - National Healthcare Security Administration held a series of discussions on the adjustment of the disease-based payment grouping scheme 3.0, involving over 70 representatives from medical institutions and industry associations [1] Drug and Medical Device Approvals - Shijiazhuang Pharmaceutical Group's application for the listing of Pertuzumab injection has been accepted by the National Medical Products Administration, targeting HER2-positive breast cancer [1] - Huason Pharmaceutical received a registration certificate for its special medical purpose formula food, Ganyimei®, designed for patients over 10 years old with strict fat restrictions and digestive absorption disorders [2] - United Imaging Healthcare's subsidiary obtained a medical device registration certificate for its color Doppler ultrasound diagnostic system, enhancing its product range across various market segments [3] - Yiling Pharmaceutical's application for the listing of Memantine Hydrochloride, a drug for treating moderate to severe Alzheimer's disease, has been approved [4] - Zhifei Biological's clinical trial application for a freeze-dried varicella inactivated vaccine has been accepted by the National Medical Products Administration [10] - Changchun High-tech's subsidiary received approval for a clinical trial of an acellular pertussis-diphtheria-tetanus combined vaccine for adolescents and adults [11] Capital Market Activities - Peking University Pharmaceutical announced the release of 34,615,386 shares from pledge, representing 51.52% of the pledged shares and 5.81% of the total share capital [5] - Kelun Pharmaceutical received approval for a registration of 4 billion yuan in ultra-short-term financing bonds, with a validity period of 2 years [6][7] - Baili Tianheng decided to delay its global offering and listing of H-shares due to current market conditions [8] - Aipeng Medical announced a plan for a shareholder to reduce holdings by up to 1% of total shares, citing personal funding needs [12] - Hendi Pharmaceutical's shareholders plan to collectively reduce their holdings by up to 2.33% of total shares for personal financial planning [13] Financial Adjustments - Baihua Pharmaceutical plans to use 1.91 billion yuan from its capital reserve to cover losses, primarily due to goodwill impairment from a previous major asset restructuring [14]